|By JCN Newswire||
|August 18, 2014 02:50 AM EDT||
Based on this agreement, Eisai will grant Zeria the exclusive rights to develop and co-promote, and the non-exclusive right to manufacture, E3710 in Japan. In addition, Eisai will receive down payment and additional royalties from Zeria, and after marketing authorization has been successfully obtained, Eisai will pay Zeria a certain consideration. While Zeria will develop E3710 and work to obtain marketing authorization, the two companies will collaborate on marketing E3710 after launch.
E3710 is a novel PPI discovered by Eisai as a successor to Pariet, and compared to existing PPIs, potentially provides a stronger and a longer-lasting inhibitory effect on gastric acid secretion. E3710 shows promise as a best-in-class treatment which could shorten the treatment period and meet the needs of patients for whom existing PPIs are inadequate.
This license agreement will enhance the product pipeline of Zeria, who focuses on gastrointestinal diseases as a key franchise area, and maximize the value of Eisai's compound. Both Eisai and Zeria have a strong track record in the field of gastrointernal diseases (Eisai with the PPI Pariet and the gastritis / gastric ulcer treatment Selbex, Zeria with the ulcerative colitis treatment Asacol and the world's first functional dyspepsia treatment Acofide) and will conduct co-promotional activities with the aim of bringing a product to the market for acid related diseases as soon as possible.
Through this collaboration on E3710, Eisai and Zeria aim to satisfy the medical needs of acid related diseases and further contribute to the treatment of patients.
Eisai Co., Ltd. (TSE: 4523; ADR: ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.
Public Relations Department, Eisai Co., Ltd. +81-3-3817-5120
Copyright 2014 JCN Newswire. All rights reserved. www.japancorp.net
May. 25, 2016 10:30 PM EDT Reads: 1,878
May. 25, 2016 10:00 PM EDT Reads: 1,064
May. 25, 2016 10:00 PM EDT Reads: 884
May. 25, 2016 09:00 PM EDT Reads: 1,770
May. 25, 2016 08:30 PM EDT Reads: 1,212
May. 25, 2016 08:15 PM EDT Reads: 2,585
May. 25, 2016 08:00 PM EDT Reads: 1,828
May. 25, 2016 07:00 PM EDT Reads: 1,056
May. 25, 2016 06:00 PM EDT Reads: 1,887
May. 25, 2016 05:45 PM EDT Reads: 484
May. 25, 2016 05:00 PM EDT Reads: 1,723
May. 25, 2016 04:45 PM EDT Reads: 951
May. 25, 2016 04:00 PM EDT Reads: 1,194
May. 25, 2016 03:45 PM EDT Reads: 2,124
May. 25, 2016 02:45 PM EDT Reads: 1,442